This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
The #NephJC chat on IgA nephropathy and the significance of crescents was quite exciting, and we were fortunate to have Dr Jonathan Barratt, one of the authors, join us for the EU chat. Thanks again to JASN for providing full text access!
The Oxford pathology classification does not include crescents in its assessment of IgA nephropathy. This was due to the low number of crescents on the initial cohort. This week's NephJC looks at a recent attempt to right this oversight.